Low-molecular-weight heparin biosimilars: Potential implications for clinical practice

Harshal Hanumant Nandurkar, Beng Hock Chong, Hatem Hassan Salem, Alexander Gallus, Vito Ferro, Ross A McKinnon

Research output: Contribution to journalArticleOtherpeer-review

Abstract

A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy. The complex nature of LMWH molecules means that it is uncertain whether a LMWH biosimilar is chemically identical to its reference product; this introduces the possibility of differences in activity and immunogenicity. The challenge for regulators and clinicians is to evaluate the level of evidence required to demonstrate that a LMWH is sufficiently similar to the reference product. The consensus opinion of the working group is that prior to clinical use a LMWH biosimilar should have proven efficacy and safety, similar to the reference product with prospective studies, which should be confirmed with a proactive post-marketing pharmacovigilance programme.
Original languageEnglish
Pages (from-to)497 - 500
Number of pages4
JournalInternal Medicine Journal
Volume44
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

Nandurkar, Harshal Hanumant ; Chong, Beng Hock ; Salem, Hatem Hassan ; Gallus, Alexander ; Ferro, Vito ; McKinnon, Ross A. / Low-molecular-weight heparin biosimilars: Potential implications for clinical practice. In: Internal Medicine Journal. 2014 ; Vol. 44, No. 5. pp. 497 - 500.
@article{7f9d236a12b34908a617e5b5ef9efcb9,
title = "Low-molecular-weight heparin biosimilars: Potential implications for clinical practice",
abstract = "A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy. The complex nature of LMWH molecules means that it is uncertain whether a LMWH biosimilar is chemically identical to its reference product; this introduces the possibility of differences in activity and immunogenicity. The challenge for regulators and clinicians is to evaluate the level of evidence required to demonstrate that a LMWH is sufficiently similar to the reference product. The consensus opinion of the working group is that prior to clinical use a LMWH biosimilar should have proven efficacy and safety, similar to the reference product with prospective studies, which should be confirmed with a proactive post-marketing pharmacovigilance programme.",
author = "Nandurkar, {Harshal Hanumant} and Chong, {Beng Hock} and Salem, {Hatem Hassan} and Alexander Gallus and Vito Ferro and McKinnon, {Ross A}",
year = "2014",
doi = "10.1111/imj.12417",
language = "English",
volume = "44",
pages = "497 -- 500",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "5",

}

Low-molecular-weight heparin biosimilars: Potential implications for clinical practice. / Nandurkar, Harshal Hanumant; Chong, Beng Hock; Salem, Hatem Hassan; Gallus, Alexander; Ferro, Vito; McKinnon, Ross A.

In: Internal Medicine Journal, Vol. 44, No. 5, 2014, p. 497 - 500.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Low-molecular-weight heparin biosimilars: Potential implications for clinical practice

AU - Nandurkar, Harshal Hanumant

AU - Chong, Beng Hock

AU - Salem, Hatem Hassan

AU - Gallus, Alexander

AU - Ferro, Vito

AU - McKinnon, Ross A

PY - 2014

Y1 - 2014

N2 - A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy. The complex nature of LMWH molecules means that it is uncertain whether a LMWH biosimilar is chemically identical to its reference product; this introduces the possibility of differences in activity and immunogenicity. The challenge for regulators and clinicians is to evaluate the level of evidence required to demonstrate that a LMWH is sufficiently similar to the reference product. The consensus opinion of the working group is that prior to clinical use a LMWH biosimilar should have proven efficacy and safety, similar to the reference product with prospective studies, which should be confirmed with a proactive post-marketing pharmacovigilance programme.

AB - A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy. The complex nature of LMWH molecules means that it is uncertain whether a LMWH biosimilar is chemically identical to its reference product; this introduces the possibility of differences in activity and immunogenicity. The challenge for regulators and clinicians is to evaluate the level of evidence required to demonstrate that a LMWH is sufficiently similar to the reference product. The consensus opinion of the working group is that prior to clinical use a LMWH biosimilar should have proven efficacy and safety, similar to the reference product with prospective studies, which should be confirmed with a proactive post-marketing pharmacovigilance programme.

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1111/imj.12417/abstract;jsessionid=6044110E4D1FAD19817B30E863805B00.f03t03

U2 - 10.1111/imj.12417

DO - 10.1111/imj.12417

M3 - Article

VL - 44

SP - 497

EP - 500

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 5

ER -